Watch PRME. Know when insiders buy.
One email the day a filing lands. Free.
PRME
Prime Medicine, Inc.
2.90
−0.17 −5.54%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
38
FLAG · shorts 38
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $526MP/E —DIV YIELD —FCF YIELD -29.82%REV TTM —NET INCOME −$187.9MNET CASH —52W 2.70 – 6.67SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$43.3M | −$42.1M | — | -0.24 | −$41M | $46K | −$41.1M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$50.7M | −$49.1M | — | -0.28 | −$42.7M | $214K | −$42.9M | Aug 6 |
| Q4 2025 · Dec 31derived | $838K | −61.6% | — | −$48.6M | −$46.1M | — | -0.24 | −$37.3M | $290K | −$37.5M | Mar 3 |
| Q3 2025 · Sep 30 | $1.2M | +486.1% | — | −$54M | −$50.6M | — | -0.32 | −$35M | $247K | −$35.3M | Nov 7 |
| Q2 2025 · Jun 30 | $1.1M | — | — | −$53.4M | −$52.6M | — | -0.41 | −$41.4M | $1.6M | −$43M | Aug 6 |
| Q1 2025 · Mar 31 | $1.5M | +146.0% | — | −$52.4M | −$51.9M | — | -0.40 | −$48.9M | $2.4M | −$51.3M | Aug 6 |
| Q4 2024 · Dec 31derived | $2.2M | — | — | −$44.2M | −$42.3M | — | -0.31 | $16.2M | $1.8M | $14.5M | Mar 3 |
| Q3 2024 · Sep 30 | $209K | — | — | −$54.2M | −$52.5M | — | -0.44 | −$25.9M | $1.3M | −$27.2M | Nov 7 |
| Q2 2024 · Jun 30 | $0 | — | — | −$55.7M | −$55.3M | — | -0.46 | −$45.5M | $1.9M | −$47.4M | Nov 7 |
| Q1 2024 · Mar 31 | $591K | — | — | −$48.3M | −$45.8M | — | -0.44 | −$67.7M | $2.3M | −$70M | Nov 7 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$68M | −$65.6M | — | -0.72 | −$43.9M | $1.8M | −$45.7M | Feb 28 |
| Q3 2023 · Sep 30 | $0 | — | — | −$51.5M | −$50.7M | — | -0.55 | −$39.2M | $2.9M | −$42.1M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $4.6M | — | −$208.3M | −$201.1M | -4342.4% | -1.35 | −$162.6M | $4.5M | −$167.1M | — | — |
| FY2024 · to Dec 31 | $3M | — | −$202.5M | −$195.9M | -6566.6% | -1.65 | −$122.9M | $7.3M | −$130.2M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$204.8M | −$198.1M | — | -2.18 | −$165.4M | $8.7M | −$174.1M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$116.5M | −$121.8M | — | -4.19 | −$131.8M | $16.1M | −$147.9M | — | — |
| FY2021 · to Dec 31 | $0 | — | −$84.5M | −$165.4M | — | -14.19 | −$34.1M | $4.2M | −$38.2M | — | — |
| FY2020 · to Dec 31 | $5.2M | — | −$932K | −$3.4M | -65.5% | -1.91 | −$5.5M | $639K | −$6.2M | — | — |
Every number comes from Prime Medicine, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.